Publications by authors named "Patrick Julier"

Claim this Profile
S
Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project.
Joanna Black, Patrick Julier, Lucy Eldridge, Vicki S Barber

Trials· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek Abhishek, Nicholas Peckham, Corinna Pade, Joseph M Gibbons, Lucy Cureton, Patrick Julier

Lancet Rheumatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.
Jennifer A E Williams, Mae Chester-Jones, Catherine Minns Lowe, Megan V Goff, Anne Francis, Patrick Julier

Lancet Rheumatol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek Abhishek, Rosemary J Boyton, Nicholas Peckham, Áine McKnight, Laura C Coates, Patrick Julier

Lancet Respir Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).
Abhishek Abhishek, R J Boyton, Áine McKnight, Laura Coates, James Bluett, Patrick Julier

BMJ Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Rachel S Kerr, Sharon Love, Eva Segelov, Elaine Johnstone, Beverly Falcon, Patrick Julier

Lancet Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Dan Rosmarin, Claire Palles, Alistair Pagnamenta, Kulvinder Kaur, Guillermo Pita, Patrick Julier

Gut· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Susan J Dutton, David R Ferry, Jane M Blazeby, Haider Abbas, Asa Dahle-Smith, Patrick Julier

Lancet Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Patrick Julier

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Rachel S Midgley, Christopher C McConkey, Elaine C Johnstone, Janet A Dunn, Justine L Smith, Patrick Julier

J Clin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
David J Kerr, Janet A Dunn, Michael J Langman, Justine L Smith, Rachel S J Midgley, Patrick Julier

N Engl J Med· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis